<DOC>
	<DOC>NCT00797225</DOC>
	<brief_summary>This study is designed to evaluate the safety and beneficial effects of NBI-56418 compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months of treatment on NBI-56418.</brief_summary>
	<brief_title>Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Inclusion Criteria Be female, aged 18 to 45 years, inclusive Have moderate to severe pelvic pain due to endometriosis Have been surgically (laparoscopy) diagnosed with endometriosis within the last 5 years and have recurrent or persistent endometriosis symptoms Have regular menstrual cycle (2333 day) Agree to use two forms of nonhormonal contraception during the study Exclusion Criteria Received a Gonadotropinreleasing hormone (GnRH) agonist, GnRH antagonist, danazol, or have received any of these agents within 6 months of the start of screening. Received subcutaneous medroxyprogesterone acetate (DMPASC) or i.m. medroxyprogesterone acetate (DMPAIM), or have received either of these agents within 3 months of the start of screening. Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month Have had surgery for endometriosis within the last month Are using systemic steroids on a chronic or regular basis within 3 months Have uterine fibroids or other pelvic lesions â‰¥3 cm in diameter Have had a hysterectomy or oophorectomy Have pelvic pain that is not caused by endometriosis Have unstable medical condition or chronic disease Have been pregnant within the last 6 months and is currently breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic Pain</keyword>
</DOC>